SEC Comment Letter 0000000000-24-003321 to Applied Therapeutics, Inc. (APLT) (CIK 0001697532)
Applied Therapeutics, Inc. (APLT) (CIK 0001697532)
Date: March 27, 2024 · CIK: 0001697532 · Accession: 0000000000-24-003321
AI Filing Summary & Sentiment
File numbers found in text: 333-278182
Letter
United States securities and exchange commission logo March 27, 2024 Shoshana Shendelman, Ph.D. President and Chief Executive Officer Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 Re:Applied Therapeutics, Inc. Registration Statement on Form S-3 Filed March 22, 2024 File No. 333-278182 Dear Shoshana Shendelman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Schwartz, Esq.
Show Raw Text
United States securities and exchange commission logo
March 27, 2024
Shoshana Shendelman, Ph.D.
President and Chief Executive Officer
Applied Therapeutics, Inc.
545 Fifth Avenue, Suite 1400
New York, NY 10017
Re:Applied Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 22, 2024
File No. 333-278182
Dear Shoshana Shendelman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael J. Schwartz, Esq.